United states food & drug administration (fda) grants mesoblast rare pediatric disease designation for revascor® (rexlemestrocel-l) in children with congenital heart disease

Revascor increases size of left heart chamber and improves surgical outcomes in children with hypoplastic left heart syndrome: results published in journal of thoracic and cardiovascular surgery open new york, jan. 18, 2024 (globe newswire) -- mesoblast limited (nasdaq:meso; asx:msb), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the united states food and drug administration (fda) has granted its allogeneic cell therapy revascor® (rexlemestrocel-l) a rare pediatric disease (rpd) designation following submission of results from the randomized controlled trial in children with hypoplastic left heart syndrome (hlhs), a potentially life threatening congenital heart condition. rpd designation is granted by the fda for certain serious or life-threatening diseases which primarily affect children.
MESO Ratings Summary
MESO Quant Ranking